Tier 4 — mechanistic

Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection

Osama Elsallabi, Antonia Patruno, Mirko Pesce, Amelia Cataldi, Simone Carradori, Marialucia Gallorini
Molecules 2022 Volume 27, page 738

Bibliography

PubMed
PMID 35164003
PubMed Central
PMC8839434
Funding
This research received no external funding.
Competing interests
The authors declare no conflict of interest.

Study snapshot

DesignLiterature review and in silico screening
ModelIn silico / computational modeling
Sample-
Intervention-
Duration-
EndpointsPrediction of biological activities, ADME (absorption, distribution, metabolism, excretion) profile, and toxicity parameters

What the study showed, in plain terms

Aging is associated with a gradual decline in brain function and an exponentially increased risk of neurodegenerative conditions like Alzheimer's and Parkinson's disease. One of the major factors driving this age-related decline is the accumulation of "senescent" cells—dysfunctional, aging cells that stop dividing but resist programmed cell death. Instead, they release a cocktail of inflammatory signals that damage surrounding brain tissue and neurons.

This review explores the potential of fisetin, a naturally occurring flavonoid found in fruits like strawberries and apples, to act as a "senotherapeutic" agent. The authors highlight emerging preclinical evidence showing that fisetin can selectively clear these toxic senescent cells from the body, reduce chronic brain inflammation, and potentially protect neurons from age-related oxidative stress and dysfunction.

In addition to reviewing existing biological studies, the researchers utilized computational (in silico) modeling to predict how fisetin behaves within the human body. Their analysis suggests that while fisetin is a safe and biologically active compound, it possesses poor water solubility and only a moderate ability to cross the blood-brain barrier. This highlights the necessity for specialized, advanced delivery systems (like liposomes or nanoparticles) to maximize its neuroprotective benefits in humans.

Key findings

  • Senolytic Activity: Fisetin is highlighted as a potent natural senolytic capable of reducing senescence markers, lowering reactive oxygen species (ROS), and extending median lifespan in animal models.
  • Neuroprotective Mechanisms: Preclinical models show fisetin attenuates neuroinflammation, decreases pro-inflammatory cytokines (like IL-1β and TNF-α), and prevents cognitive and locomotor deficits in aging mice.
  • In Silico ADME Profiling: Computational models confirm fisetin adheres to established rules for oral drug-likeness (high gastrointestinal absorption), though it suffers from limited aqueous solubility and moderate blood-brain barrier permeation.
  • Target Prediction: In silico modeling indicates a high probability (score 1.0) of fisetin interacting with key enzymes such as Cyclin-dependent kinases and Acetylcholinesterase, supporting its multi-target neuroprotective profile.
  • Safety Profile: Predictive toxicity screening characterizes fisetin as a safe lead compound, classifying it as non-mutagenic and lacking significant cytotoxic properties.

What this study can and cannot tell us

  • Preclinical and Computational Focus: As a literature review combined with in silico modeling, the pharmacodynamic and toxicity findings are theoretical and rely on predictive algorithms rather than new, direct human clinical trial data.
  • Pharmacological Hurdles: The study reinforces that fisetin's poor water solubility and rapid metabolism present significant bioavailability challenges that must be overcome before its neurological benefits can be reliably translated to human therapies.
Reviewed by , Medical Advisory Board · Last verified against PubMed on 21 July 2026